Biotinylated Monoclonal Anti-Polatuzumab Antibody, Mouse IgG1 (2H7)

1/1
製品番号/仕様
価格
Availability
数量
POB-BLMY2484-25ug
$415.00
In Stock - Delivery in 2-3 business days
POB-BLMY2484-200ug
$1,705.00
In Stock - Delivery in 2 weeks
POB-BLMY2484
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Chimeric Biotinylated Monoclonal Anti-Polatuzumab Antibody, Mouse IgG1 (2H7) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to mouse IgG1 constant domains.

Antibody Type

Recombinant Monoclonal

Clone

2H7

Isotype

Mouse IgG1, Kappa

Host Species

Mouse

Conjugate

Biotinylated

Specificity

Specifically recognizes Human Polatuzumab; This antibody is a neutralizing antibody.

Application
Application
Recommended Use / Performance
ELISA
1:20-1:200
Purification

Protein A purified.

Aggregation

Less than 5%, as determined by SEC-MALS.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

バックグランド

Polatuzumab is a genetically engineered humanized monoclonal antibody directed against the CD79b antigen (B-cell receptor complex-associated protein beta chain) found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine complementarity-determining region (CDR) sequences grafted into human framework regions of the variable domains and human constant region sequences. Polatuzumab is composed of two heavy chains of 452 amino acids and two light chains of 214 amino acids.